“…Although it is likely that the total effectiveness of these agents probably results from their action at multiple sites in the body (such as the ovary, uterine tubes, uterus, cervix, pituitary and hypothalamus), their primary action is believed to be exerted at the pituitary-hypothalamic level, inhibiting the output of luteinizing hormone (lh) and consequently ovulation (Vorys, Ullery & Stevens, 1965;Flowers, Vorys, Stevens, Miller & Jensen, 1966). Previously it has been reported that prolonged administration of a progesterone derivative, Provera, results in depletion of pituitary lh stores (Labhsetwar, 1966b), while the administration of a 19-nor steroid derivative, norethynodrel, for a period of 10 or less days was found to result in a significant increase in the pituitary lh content of the female (Labhsetwar, 1967b) as well as the male rat (Brown, Wells & Youngson, 1965).…”